Barr launches generic Accutane(R) capsules product
The Company will promote Claravis to dermatologists using its sales force that currently markets Trexall(TM) (Methotrexate Tablets, USP). Barr's comprehensive education, risk assessment and management program for patients, pharmacists and physicians includes, but is not limited to, a toll free registration program for prescriber registration and education, a website for healthcare professionals and patients, patient education materials designed to inform patients about the risks associated with use of Claravis, and a pregnancy prevention program. The risk management aspects of the program include pregnancy testing and avoidance, patient awareness and consent to avoid pregnancy, and awareness of psychiatric disorders prior to and during therapy, because Claravis can cause birth defects.
Claravis is indicated for the treatment of severe recalcitrant nodular acne. Because of significant adverse effects associated with its use, Claravis should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, for female patients of childbearing potential, Claravis is indicated only for those females who are not pregnant and will not become pregnant.
Claravis will compete in the Accutane marketplace that had total annual sales of approximately $536 million for the most recent twelve months ended March 2003
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.